Metastases and death rates after primary enucleation of unilateral retinoblastoma in the USA 2007–2017
- 25 October 2018
- journal article
- research article
- Published by BMJ in British Journal of Ophthalmology
- Vol. 103 (9) , 1272-1277
Abstract
Background/aims Enucleation for retinoblastoma is performed less often in the past decade due to increasingly widespread alternative therapies, but enucleation remains an important option. There is a paucity of reports on the current incidence of metastases and metastatic deaths in unilateral retinoblastoma from US centres. Methods Retrospective chart review at five tertiary retinoblastoma centres in the USA for unilateral retinoblastoma patients treated with primary enucleation, 2007–2017, with >1 year of follow-up or treatment failure. Results Among 228 patients (228 eyes), there were nine metastases (3.9%) and four deaths (1.7%). The Kaplan-Meier estimate at 5 years for metastasis-free survival was 96% (95% CI, 94% to 99 %), and for overall survival was 98% (95% CI 96% to 100%). All metastases were evident within 12 months. Histopathology revealed higher risk pathology (postlaminar optic nerve and/or massive choroidal invasion) in 62 of 228 eyes (27%). Of these higher risk eyes, 39 received adjuvant chemotherapy. There were four subsequent metastases in this higher risk pathology with adjuvant chemotherapy group, with three deaths. Of the nine overall with metastases, seven (78%) showed higher risk pathology. All metastatic patients were classified as Reese-Ellsworth V and International Classification of Retinoblastoma Groups D or E. Initial metastases presented as orbital invasion in seven of nine cases. Conclusions Primary enucleation for unilateral retinoblastoma results in a low rate of metastatic death, but is still associated with a 3.9% chance of metastases within a year of enucleation. Most but not all patients who developed metastases had higher risk histopathological findings.Keywords
Funding Information
- Clinical Center (P30 EY010572)
- Fund For Ophthalmic Knowledge, Inc
- MSK Cancer Center Support Grant/Core Grant (P30 CA008748)
- Research to Prevent Blindness to the Vanderbilt Department of Ophthalmology and Visual Sciences
- Research to Prevent Blindness Career Development Award
- Research to Prevent Blindness, Inc
- NIH/NEI (5K08EY027464-02)
This publication has 23 references indexed in Scilit:
- The epidemiological challenge of the most frequent eye cancer: retinoblastoma, an issue of birth and deathBritish Journal of Ophthalmology, 2009
- Published International Classification of Retinoblastoma (ICRB) Definitions Contain Inconsistencies—An Analysis of ImpactOphthalmic Genetics, 2009
- Retinoblastoma in Iran: outcomes in terms of patients' survival and globe survivalBritish Journal of Ophthalmology, 2008
- Retinoblastoma: treatment and survival in Great Britain 1963 to 2002British Journal of Ophthalmology, 2008
- Survival with retinoblastoma in the USA: 1975-2004British Journal of Ophthalmology, 2008
- Basic understanding of current classification and management of retinoblastomaCurrent Opinion in Ophthalmology, 2006
- Intraocular Retinoblastoma: the Case for a New Group ClassificationOphthalmology Clinics of North America, 2005
- Historic Review of RetinoblastomaOphthalmology, 1987
- The Treatment of Retinoblastoma by X-Ray and Triethylene MelamineArchives of Ophthalmology (1950), 1958
- Beiträge zur Kenntnis der Struktur des NetzhautgliomsGraefe's Archive for Clinical and Experimental Ophthalmology, 1911